Shares of Intra-Cellular Therapies (ITCI) are surging 35% in premarket trading Monday after Johnson & Johnson (JNJ) said it will acquire the biopharmaceutical company for roughly $14.6 billion.

Johnson & Johnson will pay Intra-Cellular shareholders $132 per share, a premium of roughly 40% to the latter's close at the end of last week. Shares jumped 15% to a record closing high of $94.87 Friday after the company announced it had settled a patent lawsuit with Sandoz, which was looking to produce and sell a generic version of Intra-Cellular's Caplyta, which treats schizophrenia and bipolar I and II depression.

The company also has other drugs in the pipeline to treat Alzheimer's Disease and Parkinson's Disease, among others.

"This acquisition further differentiates our portfolio, serves as a strategic near- and long-term growth catalyst for Johnson & Johnson and offers compelling value to patients, health systems and shareholders," Johnson & Johnson CEO Joaquin Duato said.

Deal Seen Closing Later This Year

The companies said the deal is expected to close later this ye♏ar pending approval from regulators and Intra-Cellular shareholders, with Johnson & Johnson funding the deal through a combination of cash and debt.

The pharmaceutical giant said it "will provide commentary on any potential impact to adjusted 澳洲幸运5官方开奖结果体彩网:earnings per share (EPS) from the transaction" when it provides initial full-year guidance during its fourth-quarter earnings call on 😼Jan. 22.

Intra-Cellular shares were up 35% to a record $127.90 less than an hour before the bell Monday, while Johnson & Johnson shares were little changed at $142.49.